Anadis’ Milk-Based Anti-Influenza (Flu)
Virus Antibodies to Provide Immediate Immunity
MELBOURNE, Australia (Business Wire EON/PRWEB ) January 13, 2008 --
Anadis Limited (ASX:ANX; OTC:
ANDIY), today announced major progress in its anti-flu
virus antibody program. The milk- derived anti-flu virus antibodies
are all-natural and will provide immediate-acting immune enhancement
once deposited topically on mucosal surfaces that come in contact with
the influenza virus. Results from human trials are anticipated within 18
months. Addressing both seasonal and avian influenza (bird flu) virus
strains, Anadis plans to introduce products using these antibodies (Flubodies)
into the market within 2-3 years. This decision follows several
successful animal trials with mice, conducted by Anadis and an
internationally-recognized influenza research group at the University of
Melbourne led by Professor Lorena Brown, using recognized pathways for
development of anti-avian flu virus treatments. The dairy derived
anti-flu virus antibody significantly decreased disease mortality and
were significantly interrupting the disease process after challenges
with lethal doses of virus. Anadis prototype milk-derived hyperimmune
antibody preparation ("flubody")
improved the survival rate of infected mice (exposed to lethal flu) from
0% in non-treated mice to up to 60% in treated mice. In other trials, it
was shown that the progress of disease could be delayed for days with a
single application of the prototype formulation.
“This series of new preclinical tests gives us
the comfort level to accelerate and the commercialization of our
revolutionary Flubody approach for
halting viral spread, utilizing our patent pending antibody formulations
to provide immediate acting immunity,” said Dr
Zeil Rosenberg, Anadis CEO. “Antibody and
other protein-based solutions represent the next generation in the fight
against influenza and Anadis, with its rapid development effort and
extremely low manufacturing cost for harvesting antibodies, is
well-positioned to benefit from this trend.”
Influenza affects 15-60 million people in the United States each year,
causing an estimated 44,000 deaths and 186,000 hospitalizations
annually. Pandemic influenza has occurred three times over the last
century. The 1918 outbreak alone killed more than 40 million people
worldwide. Avian influenza (bird flu) is a lethal influenza strain that
has created worldwide concern because its infection can be transferred
among humans. The mortality rate among humans exceeds 50%.
Dr. Oren Fuerst, VP of Business Development of the company said: “Benefiting
from our years of experience in the harvesting of polyclonal antibodies
and other fractions of dairy derived immune milk (colostrum), we aim to
be first to market with an effective and patented formulation for both
the routine and avian flu markets. With our unique approach, we plan to
become world leaders in the influenza market that today already exceeds
$5 billion worldwide.”
Anadis Limited (ASX: ANX; OTC:
ANDIY) is a biopharmaceutical company focused on antigen-primed,
dairy-derived health products. Anadis’
proprietary, rapid manufacturing technology has enabled it to develop a
product pipeline of polyclonal antibody-based solutions to a range of
important infectious and immune-mediated diseases. The all-natural
colostrum-derived platform, and its regulatory classification as GRAS
(Generally Regarded as Safe) when administered orally, allows for a
significantly shorter time-frame from bench to market compared with
typical biotechnology products. The platform also possesses dramatically
lower manufacturing costs and higher scalability compared to typical
antibody-based solutions. Anadis is addressing existing market
opportunities sized in excess of US$30 billion. Leveraging a technology
platform that has been carefully developed over a decade, the company
expects to become the leading provider of proprietary polyclonal
antibody-based solutions worldwide.
See the original story at: http://eon.businesswire.com/releases/anadis/influenza/prweb621771.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SG9yci1TdW1tLVN1bW0tTWFnbi1Mb3ZlLVplcm8=
Trackbacks/Comments Received
Zoloft.
from Zoloft side effects. on May 20, 2009
|
|
Going off zoloft. Uncommon side effects of zoloft. Zoloft. Zoloft and breastfeeding. Zoloft side effects. Generic zoloft.
|
|
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SG9yci1TdW1tLVN1bW0tTWFnbi1Mb3ZlLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
